According to a retrospective analysis of data from a randomized, double-blind, Phase III clinical trial, abiraterone acetate (Zytiga™) can significantly lower levels of fatigue in men with metastatic, castration-resistant prostate cancer (as well extending survival).
Filed under: Living with Prostate Cancer, Treatment | Tagged: abiraterone, castration-resistant, fatigue, metastatic | 2 Comments »

Search for new and
ongoing trials on the
CTAG PCa web site
